Elekta AB (OTCMKTS:EKTAY) Sees Significant Drop in Short Interest

Elekta AB (OTCMKTS:EKTAY) saw a large decrease in short interest in August. As of August 14th, there was short interest totaling 6,134 shares, a decrease of 62.4% from the July 30th total of 16,311 shares. Based on an average daily trading volume, of 5,460 shares, the short-interest ratio is presently 1.1 days. Currently, 0.0% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Elekta Price Performance

OTCMKTS:EKTAY opened at $5.50 on Friday. Elekta has a 1-year low of $4.35 and a 1-year high of $6.93. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.87 and a quick ratio of 0.68. The company has a 50 day moving average price of $5.19 and a 200-day moving average price of $5.70. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -34.38 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY) last issued its quarterly earnings data on Thursday, August 27th. The company reported $0.07 earnings per share for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. The business had revenue of $372.30 million during the quarter. Equities research analysts forecast that Elekta will post 0.43 EPS for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.